| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hodgkin Disease | 25 | 2023 | 1377 | 1.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 65 | 2018 | 11709 | 1.030 |
Why?
|
| Leukemia, Myeloid | 17 | 2005 | 695 | 0.840 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 11 | 2016 | 1547 | 0.710 |
Why?
|
| Bone Marrow Transplantation | 30 | 2005 | 2693 | 0.670 |
Why?
|
| Leukemia, Myeloid, Acute | 29 | 2012 | 3599 | 0.570 |
Why?
|
| Dacryocystitis | 1 | 2016 | 68 | 0.520 |
Why?
|
| Vincristine | 31 | 2014 | 1038 | 0.470 |
Why?
|
| Burkitt Lymphoma | 7 | 2018 | 333 | 0.440 |
Why?
|
| Cytarabine | 23 | 2014 | 696 | 0.420 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2014 | 167 | 0.420 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2016 | 533 | 0.420 |
Why?
|
| Idarubicin | 1 | 2012 | 59 | 0.410 |
Why?
|
| Doxorubicin | 29 | 2014 | 2209 | 0.390 |
Why?
|
| Diazepam | 1 | 2012 | 215 | 0.370 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2016 | 608 | 0.340 |
Why?
|
| Lymphoma, Non-Hodgkin | 6 | 2023 | 1373 | 0.340 |
Why?
|
| Leukemia | 10 | 2004 | 1519 | 0.340 |
Why?
|
| Lymphoma | 10 | 2023 | 1896 | 0.320 |
Why?
|
| Prednisone | 20 | 2014 | 1565 | 0.320 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 4 | 2012 | 48 | 0.300 |
Why?
|
| Child | 119 | 2021 | 79818 | 0.300 |
Why?
|
| Child, Preschool | 85 | 2019 | 42062 | 0.290 |
Why?
|
| Lymphoma, B-Cell | 4 | 2018 | 935 | 0.280 |
Why?
|
| Adolescent | 102 | 2019 | 87892 | 0.270 |
Why?
|
| Disease-Free Survival | 20 | 2014 | 6821 | 0.270 |
Why?
|
| Antineoplastic Protocols | 2 | 2005 | 50 | 0.260 |
Why?
|
| Methotrexate | 13 | 2014 | 1719 | 0.260 |
Why?
|
| Benzodiazepines | 1 | 2012 | 1130 | 0.260 |
Why?
|
| Down Syndrome | 9 | 2012 | 892 | 0.250 |
Why?
|
| Chernobyl Nuclear Accident | 1 | 2004 | 15 | 0.250 |
Why?
|
| Remission Induction | 20 | 2014 | 2388 | 0.240 |
Why?
|
| Mediastinal Neoplasms | 10 | 1995 | 402 | 0.240 |
Why?
|
| Central Nervous System Neoplasms | 4 | 2018 | 916 | 0.230 |
Why?
|
| Daunorubicin | 10 | 2012 | 156 | 0.230 |
Why?
|
| Etoposide | 9 | 2014 | 630 | 0.220 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2007 | 348 | 0.220 |
Why?
|
| Vinblastine | 6 | 2014 | 487 | 0.210 |
Why?
|
| Neoplasm Staging | 23 | 2014 | 11152 | 0.200 |
Why?
|
| Harringtonines | 1 | 2001 | 8 | 0.200 |
Why?
|
| Combined Modality Therapy | 24 | 2008 | 8530 | 0.190 |
Why?
|
| Cyclophosphamide | 12 | 2014 | 2218 | 0.170 |
Why?
|
| Prognosis | 29 | 2023 | 29557 | 0.170 |
Why?
|
| Chromosome Aberrations | 8 | 2000 | 1763 | 0.170 |
Why?
|
| Exercise Test | 1 | 2007 | 2121 | 0.170 |
Why?
|
| Procarbazine | 7 | 2004 | 172 | 0.170 |
Why?
|
| Infant | 45 | 2014 | 36055 | 0.160 |
Why?
|
| Leukemia, Lymphoid | 7 | 1988 | 310 | 0.160 |
Why?
|
| Whole-Body Irradiation | 3 | 1998 | 433 | 0.160 |
Why?
|
| Myeloproliferative Disorders | 3 | 2017 | 606 | 0.150 |
Why?
|
| Recurrence | 18 | 2013 | 8426 | 0.150 |
Why?
|
| Splenomegaly | 2 | 2017 | 189 | 0.150 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2001 | 623 | 0.140 |
Why?
|
| Acute Disease | 18 | 2005 | 7225 | 0.140 |
Why?
|
| Survival Rate | 17 | 2014 | 12721 | 0.140 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 1999 | 255 | 0.140 |
Why?
|
| STAT Transcription Factors | 1 | 2017 | 188 | 0.140 |
Why?
|
| Janus Kinases | 1 | 2017 | 249 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 4 | 2014 | 693 | 0.130 |
Why?
|
| Humans | 154 | 2023 | 758406 | 0.130 |
Why?
|
| Lymphoma, Follicular | 2 | 2012 | 453 | 0.130 |
Why?
|
| Male | 94 | 2021 | 358747 | 0.130 |
Why?
|
| Survival Analysis | 15 | 2010 | 10112 | 0.130 |
Why?
|
| Drug Administration Schedule | 11 | 2014 | 4839 | 0.130 |
Why?
|
| Critical Pathways | 1 | 2019 | 473 | 0.120 |
Why?
|
| Thioguanine | 4 | 2000 | 44 | 0.120 |
Why?
|
| Antineoplastic Agents | 15 | 2003 | 13591 | 0.120 |
Why?
|
| Leukemia, Promyelocytic, Acute | 2 | 2009 | 251 | 0.120 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2017 | 423 | 0.120 |
Why?
|
| Tretinoin | 3 | 2009 | 519 | 0.120 |
Why?
|
| Abdominal Neoplasms | 3 | 1992 | 286 | 0.120 |
Why?
|
| Female | 95 | 2021 | 390323 | 0.120 |
Why?
|
| Neuroblastoma | 3 | 2000 | 1251 | 0.120 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 5 | 2005 | 1402 | 0.110 |
Why?
|
| Treatment Outcome | 29 | 2018 | 64378 | 0.110 |
Why?
|
| Length of Stay | 1 | 2007 | 6439 | 0.110 |
Why?
|
| Neutropenia | 5 | 2012 | 884 | 0.110 |
Why?
|
| Nervous System Neoplasms | 3 | 1990 | 91 | 0.110 |
Why?
|
| Haemophilus Vaccines | 4 | 1997 | 71 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 21 | 2 | 2006 | 228 | 0.100 |
Why?
|
| Leukocyte Count | 8 | 2006 | 1593 | 0.100 |
Why?
|
| Cyclosporine | 3 | 2005 | 777 | 0.100 |
Why?
|
| Gene Rearrangement | 2 | 2012 | 1122 | 0.100 |
Why?
|
| Prednisolone | 8 | 2001 | 326 | 0.100 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 1999 | 1348 | 0.100 |
Why?
|
| Salvage Therapy | 4 | 2010 | 1268 | 0.100 |
Why?
|
| Adult | 57 | 2021 | 219935 | 0.100 |
Why?
|
| Neoplasm, Residual | 2 | 2015 | 1007 | 0.090 |
Why?
|
| Life Tables | 5 | 2002 | 365 | 0.090 |
Why?
|
| Outpatients | 1 | 2019 | 1591 | 0.090 |
Why?
|
| Cyclosporins | 1 | 2010 | 216 | 0.090 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 1990 | 38 | 0.090 |
Why?
|
| Core Binding Factors | 1 | 2010 | 29 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2012 | 1404 | 0.090 |
Why?
|
| Infusions, Intravenous | 6 | 2014 | 2210 | 0.090 |
Why?
|
| Immunophenotyping | 5 | 2012 | 1871 | 0.080 |
Why?
|
| Mitoxantrone | 3 | 2010 | 148 | 0.080 |
Why?
|
| Caregivers | 1 | 2021 | 2225 | 0.080 |
Why?
|
| Immunotherapy, Active | 3 | 1998 | 59 | 0.080 |
Why?
|
| Myelodysplastic Syndromes | 5 | 1997 | 1392 | 0.080 |
Why?
|
| Health Expenditures | 1 | 2021 | 2347 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 4 | 2003 | 1705 | 0.080 |
Why?
|
| Leukemia, B-Cell | 1 | 2009 | 84 | 0.080 |
Why?
|
| Follow-Up Studies | 17 | 2014 | 39059 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2012 | 9273 | 0.080 |
Why?
|
| Graft vs Host Disease | 8 | 1997 | 3024 | 0.080 |
Why?
|
| Injections, Spinal | 3 | 2018 | 317 | 0.080 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 1988 | 27 | 0.080 |
Why?
|
| Infant, Newborn | 15 | 2012 | 26183 | 0.070 |
Why?
|
| Drug Resistance, Multiple | 3 | 2010 | 253 | 0.070 |
Why?
|
| Kidney Diseases | 2 | 1988 | 2083 | 0.070 |
Why?
|
| Anemia, Hemolytic | 1 | 1988 | 163 | 0.070 |
Why?
|
| Inpatients | 1 | 2019 | 2551 | 0.070 |
Why?
|
| Azacitidine | 2 | 2000 | 334 | 0.070 |
Why?
|
| Trachea | 2 | 1995 | 1081 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2010 | 726 | 0.070 |
Why?
|
| Echocardiography, Stress | 1 | 2006 | 134 | 0.070 |
Why?
|
| Bone Neoplasms | 4 | 1999 | 2531 | 0.060 |
Why?
|
| Lung Neoplasms | 3 | 2007 | 13245 | 0.060 |
Why?
|
| Soft Tissue Neoplasms | 3 | 1988 | 1152 | 0.060 |
Why?
|
| Leukocytosis | 2 | 2003 | 251 | 0.060 |
Why?
|
| Karyotyping | 6 | 2005 | 1171 | 0.060 |
Why?
|
| Mosaicism | 2 | 2006 | 465 | 0.060 |
Why?
|
| Republic of Belarus | 1 | 2004 | 38 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2002 | 2640 | 0.060 |
Why?
|
| Plasmacytoma | 1 | 1985 | 171 | 0.060 |
Why?
|
| Bone Marrow | 7 | 2014 | 2909 | 0.060 |
Why?
|
| Forced Expiratory Volume | 2 | 2007 | 1806 | 0.060 |
Why?
|
| Chromosomes, Human, 16-18 | 1 | 1984 | 32 | 0.060 |
Why?
|
| Trisomy | 1 | 2006 | 260 | 0.060 |
Why?
|
| GATA1 Transcription Factor | 1 | 2005 | 296 | 0.060 |
Why?
|
| Histological Techniques | 1 | 2004 | 194 | 0.060 |
Why?
|
| Ukraine | 1 | 2004 | 138 | 0.060 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 1998 | 886 | 0.060 |
Why?
|
| Radiotherapy Dosage | 5 | 2002 | 2896 | 0.060 |
Why?
|
| Russia | 1 | 2004 | 381 | 0.060 |
Why?
|
| Young Adult | 8 | 2014 | 58808 | 0.060 |
Why?
|
| Lung Diseases | 3 | 2002 | 1910 | 0.060 |
Why?
|
| Fibrosarcoma | 1 | 1985 | 308 | 0.060 |
Why?
|
| Bone Marrow Examination | 2 | 2003 | 154 | 0.050 |
Why?
|
| Cystathionine beta-Synthase | 1 | 2002 | 27 | 0.050 |
Why?
|
| Leukemia, Radiation-Induced | 3 | 1998 | 39 | 0.050 |
Why?
|
| Radiotherapy | 3 | 1990 | 1504 | 0.050 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 1985 | 286 | 0.050 |
Why?
|
| Mechlorethamine | 5 | 1993 | 129 | 0.050 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2004 | 219 | 0.050 |
Why?
|
| Antibodies, Bacterial | 3 | 1997 | 1468 | 0.050 |
Why?
|
| Switzerland | 1 | 2023 | 323 | 0.050 |
Why?
|
| Pediatrics | 1 | 2017 | 3587 | 0.050 |
Why?
|
| Tetanus Toxoid | 3 | 1997 | 193 | 0.050 |
Why?
|
| Lymph Nodes | 3 | 2012 | 3485 | 0.050 |
Why?
|
| Cranial Irradiation | 2 | 1997 | 390 | 0.050 |
Why?
|
| Vomiting | 2 | 2012 | 651 | 0.050 |
Why?
|
| Pneumonectomy | 2 | 2007 | 1111 | 0.050 |
Why?
|
| Chromosome Disorders | 2 | 2000 | 499 | 0.050 |
Why?
|
| Translocation, Genetic | 3 | 2010 | 1387 | 0.050 |
Why?
|
| Transplantation, Autologous | 5 | 1997 | 2114 | 0.050 |
Why?
|
| Genes, MDR | 1 | 2000 | 36 | 0.040 |
Why?
|
| Mediastinum | 3 | 1986 | 266 | 0.040 |
Why?
|
| Disease Progression | 4 | 2012 | 13468 | 0.040 |
Why?
|
| Drug Therapy, Combination | 11 | 1997 | 6293 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2002 | 1791 | 0.040 |
Why?
|
| Cancer Vaccines | 2 | 1998 | 1046 | 0.040 |
Why?
|
| Chromosome Inversion | 1 | 2000 | 120 | 0.040 |
Why?
|
| Pericardial Effusion | 1 | 2002 | 247 | 0.040 |
Why?
|
| Rhabdomyosarcoma | 3 | 1990 | 358 | 0.040 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2003 | 241 | 0.040 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2008 | 2004 | 0.040 |
Why?
|
| Retrospective Studies | 16 | 2017 | 80168 | 0.040 |
Why?
|
| Hospitalization | 1 | 2019 | 10652 | 0.040 |
Why?
|
| Eosinophils | 1 | 1984 | 946 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 5 | 1996 | 3384 | 0.040 |
Why?
|
| Neoplasms | 3 | 2021 | 22032 | 0.040 |
Why?
|
| Fever of Unknown Origin | 1 | 2019 | 94 | 0.040 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 1999 | 136 | 0.040 |
Why?
|
| Vaccines, Conjugate | 2 | 1997 | 328 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 2 | 1996 | 2457 | 0.040 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 1999 | 638 | 0.040 |
Why?
|
| Risk Factors | 8 | 2007 | 73809 | 0.040 |
Why?
|
| Fatal Outcome | 2 | 2002 | 1829 | 0.040 |
Why?
|
| Chromosomes, Human | 1 | 2000 | 442 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2023 | 799 | 0.040 |
Why?
|
| Perphenazine | 1 | 1997 | 33 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2017 | 7810 | 0.040 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2003 | 708 | 0.040 |
Why?
|
| Diphenhydramine | 1 | 1997 | 63 | 0.040 |
Why?
|
| Diaphragm | 2 | 1990 | 351 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 2 | 2007 | 2882 | 0.040 |
Why?
|
| Antigens, Surface | 4 | 1992 | 1607 | 0.040 |
Why?
|
| HL-60 Cells | 1 | 1998 | 363 | 0.040 |
Why?
|
| Maternal-Fetal Exchange | 1 | 1999 | 463 | 0.040 |
Why?
|
| Neoplasm Transplantation | 2 | 1998 | 2013 | 0.040 |
Why?
|
| Leukemic Infiltration | 1 | 1997 | 47 | 0.040 |
Why?
|
| Electrocardiography | 2 | 2007 | 6363 | 0.040 |
Why?
|
| Ondansetron | 1 | 1997 | 95 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2002 | 3527 | 0.030 |
Why?
|
| Haemophilus influenzae | 1 | 1997 | 180 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2004 | 1613 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 2 | 1997 | 1454 | 0.030 |
Why?
|
| Dopamine Antagonists | 1 | 1997 | 288 | 0.030 |
Why?
|
| Amsacrine | 1 | 1996 | 19 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2012 | 10416 | 0.030 |
Why?
|
| Uganda | 1 | 2021 | 1324 | 0.030 |
Why?
|
| Laparotomy | 3 | 1994 | 465 | 0.030 |
Why?
|
| Hydromorphone | 1 | 1996 | 70 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2001 | 5249 | 0.030 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 1996 | 116 | 0.030 |
Why?
|
| Middle Aged | 27 | 2012 | 219568 | 0.030 |
Why?
|
| Haemophilus Infections | 1 | 1996 | 94 | 0.030 |
Why?
|
| Mucopolysaccharidosis I | 1 | 1996 | 52 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 6493 | 0.030 |
Why?
|
| Antiemetics | 1 | 1997 | 187 | 0.030 |
Why?
|
| Leukemia, Experimental | 1 | 1996 | 225 | 0.030 |
Why?
|
| Age Factors | 6 | 2005 | 18358 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1999 | 675 | 0.030 |
Why?
|
| Clone Cells | 2 | 1995 | 1660 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2000 | 5649 | 0.030 |
Why?
|
| Antigens, Neoplasm | 5 | 1992 | 1997 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 1999 | 1900 | 0.030 |
Why?
|
| Teratoma | 2 | 1991 | 403 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 4 | 1997 | 1628 | 0.030 |
Why?
|
| Meninges | 1 | 1997 | 197 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2006 | 8506 | 0.030 |
Why?
|
| Typhlitis | 1 | 2014 | 2 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 5 | 2009 | 9160 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2017 | 627 | 0.030 |
Why?
|
| Dactinomycin | 4 | 1999 | 304 | 0.030 |
Why?
|
| Polysaccharides, Bacterial | 2 | 1996 | 574 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2017 | 23342 | 0.030 |
Why?
|
| Research Report | 1 | 2017 | 367 | 0.030 |
Why?
|
| Blast Crisis | 2 | 2006 | 101 | 0.030 |
Why?
|
| Actuarial Analysis | 3 | 1990 | 374 | 0.030 |
Why?
|
| Graft Survival | 5 | 1996 | 3794 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2000 | 6234 | 0.030 |
Why?
|
| Sialoglycoproteins | 1 | 1994 | 315 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2005 | 10748 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2001 | 1171 | 0.030 |
Why?
|
| Receptors, Interleukin-1 | 1 | 1994 | 261 | 0.030 |
Why?
|
| Granulocytes | 3 | 1992 | 550 | 0.030 |
Why?
|
| Mucous Membrane | 1 | 1996 | 656 | 0.030 |
Why?
|
| Genes, myc | 1 | 2014 | 391 | 0.030 |
Why?
|
| Cell Separation | 2 | 1996 | 1720 | 0.030 |
Why?
|
| Lymphokines | 2 | 1997 | 926 | 0.030 |
Why?
|
| Lung | 2 | 1995 | 9985 | 0.030 |
Why?
|
| Biopsy | 3 | 2003 | 6768 | 0.030 |
Why?
|
| Leukocytes | 2 | 1999 | 2025 | 0.030 |
Why?
|
| Morphine | 1 | 1996 | 653 | 0.030 |
Why?
|
| Aged | 12 | 2012 | 168218 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2000 | 5864 | 0.020 |
Why?
|
| Sarcoma | 2 | 1988 | 1785 | 0.020 |
Why?
|
| Blood Transfusion | 3 | 1988 | 1321 | 0.020 |
Why?
|
| Mutation | 4 | 2010 | 29915 | 0.020 |
Why?
|
| Pilot Projects | 3 | 2015 | 8553 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 4485 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2012 | 270 | 0.020 |
Why?
|
| Time Factors | 12 | 2001 | 39872 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 6457 | 0.020 |
Why?
|
| Predictive Value of Tests | 3 | 2006 | 15225 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 2003 | 2244 | 0.020 |
Why?
|
| Anthracyclines | 1 | 2013 | 282 | 0.020 |
Why?
|
| Antigens, CD | 2 | 2001 | 3997 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2004 | 23884 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2021 | 2976 | 0.020 |
Why?
|
| Mothers | 1 | 2021 | 2189 | 0.020 |
Why?
|
| Immunotherapy | 2 | 2018 | 4641 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 1997 | 1588 | 0.020 |
Why?
|
| Asparaginase | 1 | 2012 | 240 | 0.020 |
Why?
|
| Genital Neoplasms, Male | 1 | 1990 | 68 | 0.020 |
Why?
|
| Carboplatin | 2 | 2009 | 788 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2012 | 631 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 1999 | 2201 | 0.020 |
Why?
|
| Self Report | 1 | 2021 | 3714 | 0.020 |
Why?
|
| Hypergammaglobulinemia | 1 | 1989 | 72 | 0.020 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1995 | 685 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 1998 | 1346 | 0.020 |
Why?
|
| DNA Primers | 2 | 2005 | 2816 | 0.020 |
Why?
|
| Tissue Donors | 2 | 1996 | 2311 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2004 | 22029 | 0.020 |
Why?
|
| Pigmentation Disorders | 1 | 1990 | 105 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 3 | 2005 | 6127 | 0.020 |
Why?
|
| Steroids | 1 | 1994 | 926 | 0.020 |
Why?
|
| Medicine | 1 | 2017 | 942 | 0.020 |
Why?
|
| Nausea | 1 | 2012 | 677 | 0.020 |
Why?
|
| Multiple Myeloma | 2 | 1994 | 5129 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 1999 | 1996 | 0.020 |
Why?
|
| Brain Neoplasms | 3 | 2005 | 8981 | 0.020 |
Why?
|
| Herpes Simplex | 1 | 1992 | 478 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 2 | 1995 | 1056 | 0.020 |
Why?
|
| Aged, 80 and over | 3 | 2012 | 58683 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2002 | 2782 | 0.020 |
Why?
|
| Anesthesia, Local | 1 | 1991 | 276 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 2 | 1994 | 1826 | 0.020 |
Why?
|
| Ifosfamide | 1 | 2009 | 232 | 0.020 |
Why?
|
| Blood Urea Nitrogen | 1 | 1988 | 186 | 0.020 |
Why?
|
| Vaccines | 1 | 1997 | 832 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2004 | 9404 | 0.020 |
Why?
|
| Clinical Trials as Topic | 3 | 1999 | 7985 | 0.020 |
Why?
|
| Cluster Analysis | 2 | 2005 | 2697 | 0.020 |
Why?
|
| Immunoglobulin G | 2 | 1997 | 4540 | 0.020 |
Why?
|
| Urogenital Neoplasms | 1 | 1989 | 135 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 876 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2000 | 12440 | 0.020 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 1989 | 179 | 0.020 |
Why?
|
| Genes, ras | 1 | 1990 | 654 | 0.020 |
Why?
|
| Immunoglobulin A | 2 | 1994 | 979 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1996 | 2532 | 0.020 |
Why?
|
| Monosomy | 1 | 1986 | 52 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 1998 | 3705 | 0.020 |
Why?
|
| Bacterial Infections | 3 | 2003 | 1401 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 4 | 2002 | 6068 | 0.020 |
Why?
|
| Immunosuppressive Agents | 4 | 2005 | 4158 | 0.020 |
Why?
|
| Thoracic Neoplasms | 1 | 1989 | 266 | 0.020 |
Why?
|
| Risk | 4 | 1987 | 9599 | 0.020 |
Why?
|
| Mediastinal Emphysema | 1 | 1986 | 29 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2005 | 3774 | 0.020 |
Why?
|
| HLA Antigens | 2 | 1990 | 1368 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2004 | 20055 | 0.020 |
Why?
|
| United States | 7 | 2003 | 72136 | 0.020 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1990 | 557 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2012 | 2504 | 0.020 |
Why?
|
| Mitolactol | 1 | 2005 | 13 | 0.020 |
Why?
|
| Neoplasm Metastasis | 4 | 2001 | 4901 | 0.020 |
Why?
|
| Transplantation, Homologous | 4 | 1996 | 4809 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 2796 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 5 | 1995 | 20500 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 1986 | 310 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 4567 | 0.020 |
Why?
|
| Decision Making | 1 | 2000 | 3915 | 0.020 |
Why?
|
| Neuralgia | 1 | 2012 | 600 | 0.020 |
Why?
|
| Cohort Studies | 3 | 2012 | 41256 | 0.020 |
Why?
|
| Neprilysin | 1 | 1988 | 471 | 0.020 |
Why?
|
| Cytokines | 2 | 1998 | 7338 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 1988 | 911 | 0.020 |
Why?
|
| Preleukemia | 1 | 1985 | 34 | 0.020 |
Why?
|
| Diagnosis, Differential | 4 | 2007 | 12951 | 0.020 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 1985 | 169 | 0.020 |
Why?
|
| Bacterial Vaccines | 2 | 1996 | 401 | 0.020 |
Why?
|
| Lung Diseases, Fungal | 1 | 1985 | 126 | 0.020 |
Why?
|
| Prospective Studies | 6 | 2012 | 54137 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 1987 | 2943 | 0.020 |
Why?
|
| Mice, Inbred Strains | 2 | 1998 | 1759 | 0.020 |
Why?
|
| Phosphoglycerate Kinase | 2 | 1995 | 66 | 0.020 |
Why?
|
| Enterocolitis | 1 | 1986 | 106 | 0.010 |
Why?
|
| Eye Neoplasms | 1 | 1986 | 306 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1985 | 700 | 0.010 |
Why?
|
| Core Binding Factor Alpha 3 Subunit | 1 | 2004 | 57 | 0.010 |
Why?
|
| Hematopoiesis | 1 | 1994 | 2047 | 0.010 |
Why?
|
| Enzymes | 1 | 2006 | 258 | 0.010 |
Why?
|
| Drug Hypersensitivity | 1 | 1993 | 915 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 1984 | 260 | 0.010 |
Why?
|
| Bilirubin | 1 | 2006 | 437 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2005 | 1304 | 0.010 |
Why?
|
| Retinoblastoma | 1 | 1986 | 317 | 0.010 |
Why?
|
| Radiography | 2 | 1986 | 6954 | 0.010 |
Why?
|
| Luciferases | 1 | 2005 | 714 | 0.010 |
Why?
|
| Erythropoiesis | 1 | 1988 | 682 | 0.010 |
Why?
|
| Exons | 1 | 2010 | 2387 | 0.010 |
Why?
|
| Anesthesia, General | 1 | 1991 | 1165 | 0.010 |
Why?
|
| Agranulocytosis | 1 | 1983 | 99 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 1997 | 4549 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2000 | 10146 | 0.010 |
Why?
|
| Methods | 2 | 1988 | 1074 | 0.010 |
Why?
|
| Particle Accelerators | 1 | 1983 | 174 | 0.010 |
Why?
|
| Bronchitis | 1 | 2003 | 196 | 0.010 |
Why?
|
| Immunization | 3 | 1996 | 1227 | 0.010 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1985 | 263 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1985 | 1705 | 0.010 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2007 | 1110 | 0.010 |
Why?
|
| Cardiovascular Diseases | 2 | 2006 | 15399 | 0.010 |
Why?
|
| Bleomycin | 2 | 1993 | 495 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1985 | 2557 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 1982 | 398 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 1986 | 1387 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 2002 | 361 | 0.010 |
Why?
|
| Herpesviridae Infections | 1 | 2003 | 270 | 0.010 |
Why?
|
| Apoptosis | 1 | 1998 | 9468 | 0.010 |
Why?
|
| Lymphography | 2 | 1994 | 188 | 0.010 |
Why?
|
| Erythrocyte Count | 1 | 2002 | 157 | 0.010 |
Why?
|
| Reoperation | 1 | 1992 | 4282 | 0.010 |
Why?
|
| Cytoplasmic Granules | 1 | 1984 | 573 | 0.010 |
Why?
|
| Pain | 1 | 1996 | 5065 | 0.010 |
Why?
|
| Interleukin-4 | 2 | 1998 | 1130 | 0.010 |
Why?
|
| Cross-Over Studies | 2 | 1997 | 2048 | 0.010 |
Why?
|
| Tamoxifen | 1 | 2005 | 963 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1985 | 1514 | 0.010 |
Why?
|
| Megakaryocytes | 2 | 2002 | 565 | 0.010 |
Why?
|
| Remission, Spontaneous | 2 | 1978 | 384 | 0.010 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2004 | 495 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 1994 | 3824 | 0.010 |
Why?
|
| Analgesics, Opioid | 1 | 1996 | 3765 | 0.010 |
Why?
|
| Dacarbazine | 2 | 1993 | 559 | 0.010 |
Why?
|
| Pregnancy | 2 | 1999 | 29742 | 0.010 |
Why?
|
| Logistic Models | 2 | 2006 | 13276 | 0.010 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1985 | 494 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 1991 | 5199 | 0.010 |
Why?
|
| Leukocyte Transfusion | 1 | 1979 | 56 | 0.010 |
Why?
|
| Graft vs Host Reaction | 1 | 1979 | 103 | 0.010 |
Why?
|
| Blood Component Removal | 1 | 2000 | 132 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 1980 | 384 | 0.010 |
Why?
|
| Central Nervous System Diseases | 2 | 1981 | 520 | 0.010 |
Why?
|
| DNA Helicases | 1 | 2004 | 854 | 0.010 |
Why?
|
| Preoperative Care | 1 | 1988 | 2249 | 0.010 |
Why?
|
| Polymorphism, Genetic | 2 | 2002 | 4284 | 0.010 |
Why?
|
| Benzamides | 1 | 2004 | 1368 | 0.010 |
Why?
|
| Exanthema | 1 | 2003 | 504 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2002 | 1539 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2002 | 1632 | 0.010 |
Why?
|
| Quality of Life | 1 | 1999 | 13285 | 0.010 |
Why?
|
| Transfection | 1 | 2005 | 5779 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2002 | 1414 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2006 | 3680 | 0.010 |
Why?
|
| DNA, Neoplasm | 2 | 1994 | 1745 | 0.010 |
Why?
|
| Therapeutic Equivalency | 1 | 1996 | 134 | 0.010 |
Why?
|
| Iduronidase | 1 | 1996 | 31 | 0.010 |
Why?
|
| Platelet Transfusion | 1 | 1979 | 294 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 1989 | 4738 | 0.010 |
Why?
|
| S Phase | 1 | 1997 | 422 | 0.010 |
Why?
|
| Recombinant Proteins | 2 | 1997 | 6520 | 0.010 |
Why?
|
| Maximal Expiratory Flow Rate | 1 | 1995 | 42 | 0.010 |
Why?
|
| Incidence | 2 | 2006 | 21272 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 1997 | 223 | 0.010 |
Why?
|
| Leukapheresis | 1 | 1996 | 134 | 0.010 |
Why?
|
| Antibodies | 1 | 2003 | 2420 | 0.010 |
Why?
|
| Radiotherapy, High-Energy | 2 | 1990 | 228 | 0.010 |
Why?
|
| Bacterial Capsules | 1 | 1996 | 242 | 0.010 |
Why?
|
| Leucovorin | 1 | 1977 | 641 | 0.010 |
Why?
|
| Heart Rate | 1 | 2006 | 4166 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1997 | 629 | 0.010 |
Why?
|
| Pneumonia | 1 | 1986 | 2129 | 0.010 |
Why?
|
| Kinetics | 1 | 1982 | 6371 | 0.010 |
Why?
|
| Sinusitis | 1 | 2003 | 990 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 1983 | 2825 | 0.010 |
Why?
|
| Piperazines | 1 | 2004 | 2511 | 0.010 |
Why?
|
| Dosage Compensation, Genetic | 1 | 1995 | 207 | 0.010 |
Why?
|
| Antibody Formation | 2 | 1994 | 1400 | 0.010 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 1995 | 210 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1994 | 852 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 1994 | 298 | 0.010 |
Why?
|
| Streptococcus pneumoniae | 1 | 1978 | 732 | 0.010 |
Why?
|
| Kidney | 1 | 1988 | 7016 | 0.010 |
Why?
|
| Stroke Volume | 1 | 2006 | 5460 | 0.010 |
Why?
|
| Prevalence | 1 | 2010 | 15651 | 0.010 |
Why?
|
| Animals | 6 | 1998 | 167768 | 0.010 |
Why?
|
| Pneumococcal Vaccines | 1 | 1996 | 397 | 0.010 |
Why?
|
| Anemia, Aplastic | 1 | 1994 | 228 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2004 | 3006 | 0.010 |
Why?
|
| Concanavalin A | 1 | 1991 | 190 | 0.010 |
Why?
|
| Th1 Cells | 1 | 1997 | 1031 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2003 | 2821 | 0.010 |
Why?
|
| Acyclovir | 1 | 1992 | 268 | 0.010 |
Why?
|
| Testicular Neoplasms | 2 | 1989 | 801 | 0.010 |
Why?
|
| Mice, Nude | 1 | 1998 | 3602 | 0.010 |
Why?
|
| Vaccines, Synthetic | 1 | 1994 | 617 | 0.010 |
Why?
|
| X Chromosome | 1 | 1995 | 815 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 14641 | 0.010 |
Why?
|
| Osteosarcoma | 1 | 1977 | 897 | 0.010 |
Why?
|
| T-Lymphocytes | 3 | 1990 | 10171 | 0.010 |
Why?
|
| Research Design | 1 | 2006 | 6157 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1991 | 818 | 0.010 |
Why?
|
| Probability | 2 | 1990 | 2467 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 1995 | 1680 | 0.010 |
Why?
|
| Mice | 4 | 1998 | 81101 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1997 | 1765 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1986 | 14490 | 0.010 |
Why?
|
| Hair Color | 1 | 1990 | 131 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1998 | 1807 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2004 | 5786 | 0.010 |
Why?
|
| DNA Probes | 1 | 1990 | 543 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1998 | 3733 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1994 | 1529 | 0.010 |
Why?
|
| Neutrophils | 1 | 2002 | 3765 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1983 | 9267 | 0.000 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 15785 | 0.000 |
Why?
|
| Lymphocyte Depletion | 1 | 1990 | 602 | 0.000 |
Why?
|
| Primary Myelofibrosis | 1 | 1990 | 208 | 0.000 |
Why?
|
| Receptors, Androgen | 1 | 1995 | 1077 | 0.000 |
Why?
|
| Orchiectomy | 1 | 1990 | 470 | 0.000 |
Why?
|
| Codon | 1 | 1990 | 602 | 0.000 |
Why?
|
| Drug Resistance | 1 | 1994 | 1593 | 0.000 |
Why?
|
| Macrophages | 1 | 1983 | 5737 | 0.000 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 17768 | 0.000 |
Why?
|
| Genotype | 1 | 2002 | 12945 | 0.000 |
Why?
|
| Diarrhea | 1 | 1994 | 1317 | 0.000 |
Why?
|
| Immunohistochemistry | 1 | 2001 | 11070 | 0.000 |
Why?
|
| Heterozygote | 1 | 1994 | 2797 | 0.000 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 9574 | 0.000 |
Why?
|
| Dysgerminoma | 1 | 1986 | 66 | 0.000 |
Why?
|
| Colony-Forming Units Assay | 1 | 1986 | 351 | 0.000 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1998 | 4342 | 0.000 |
Why?
|
| Pain Measurement | 1 | 1996 | 3527 | 0.000 |
Why?
|
| Penicillium | 1 | 1985 | 22 | 0.000 |
Why?
|
| Lymphocyte Activation | 1 | 1997 | 5490 | 0.000 |
Why?
|
| Heart Arrest | 1 | 1996 | 1494 | 0.000 |
Why?
|
| Cause of Death | 1 | 1996 | 3675 | 0.000 |
Why?
|
| Leukopenia | 1 | 1985 | 211 | 0.000 |
Why?
|
| Body Weight | 1 | 1996 | 4603 | 0.000 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1989 | 586 | 0.000 |
Why?
|
| Interleukin-2 | 1 | 1991 | 1888 | 0.000 |
Why?
|
| Transcription Factors | 1 | 2004 | 12094 | 0.000 |
Why?
|
| Lymph Node Excision | 1 | 1990 | 1303 | 0.000 |
Why?
|
| Cell Division | 1 | 1991 | 4458 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 2006 | 15637 | 0.000 |
Why?
|
| Naphthol AS D Esterase | 1 | 1983 | 14 | 0.000 |
Why?
|
| Aspergillosis | 1 | 1985 | 243 | 0.000 |
Why?
|
| Genital Neoplasms, Female | 1 | 1989 | 533 | 0.000 |
Why?
|
| Syndrome | 1 | 1990 | 3262 | 0.000 |
Why?
|
| Diploidy | 1 | 1983 | 132 | 0.000 |
Why?
|
| Metaphase | 1 | 1983 | 144 | 0.000 |
Why?
|
| Interferon-gamma | 1 | 1991 | 3156 | 0.000 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1985 | 881 | 0.000 |
Why?
|
| Neuropsychological Tests | 1 | 1996 | 7021 | 0.000 |
Why?
|
| Candidiasis | 1 | 1985 | 363 | 0.000 |
Why?
|
| Radiation Injuries | 1 | 1990 | 1182 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 1996 | 12262 | 0.000 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 1990 | 1725 | 0.000 |
Why?
|
| Pedigree | 1 | 1990 | 4578 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1980 | 7403 | 0.000 |
Why?
|
| DNA Mutational Analysis | 1 | 1990 | 4106 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1997 | 18940 | 0.000 |
Why?
|
| Neoplasm Invasiveness | 1 | 1989 | 3617 | 0.000 |
Why?
|
| DNA | 1 | 1995 | 7199 | 0.000 |
Why?
|
| Peroxidase | 1 | 1983 | 605 | 0.000 |
Why?
|
| Genetic Markers | 1 | 1986 | 2608 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 36284 | 0.000 |
Why?
|
| Gene Expression | 1 | 1992 | 7583 | 0.000 |
Why?
|
| Thyroid Diseases | 1 | 1983 | 386 | 0.000 |
Why?
|
| Emergencies | 1 | 1986 | 1209 | 0.000 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1979 | 58 | 0.000 |
Why?
|
| Horses | 1 | 1980 | 298 | 0.000 |
Why?
|
| RNA, Messenger | 1 | 1994 | 12759 | 0.000 |
Why?
|
| Sex Factors | 1 | 1993 | 10504 | 0.000 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1983 | 1446 | 0.000 |
Why?
|
| Alleles | 1 | 1990 | 6895 | 0.000 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1986 | 1110 | 0.000 |
Why?
|
| Antilymphocyte Serum | 1 | 1980 | 482 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 1997 | 18119 | 0.000 |
Why?
|
| Fever | 1 | 1986 | 1617 | 0.000 |
Why?
|
| Growth Disorders | 1 | 1983 | 653 | 0.000 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 1980 | 545 | 0.000 |
Why?
|
| Splenectomy | 1 | 1978 | 391 | 0.000 |
Why?
|
| Inflammation | 1 | 1996 | 10718 | 0.000 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1989 | 2276 | 0.000 |
Why?
|
| Infertility | 1 | 1983 | 655 | 0.000 |
Why?
|
| Bone Marrow Cells | 1 | 1983 | 2414 | 0.000 |
Why?
|
| Phenotype | 2 | 1983 | 16534 | 0.000 |
Why?
|
| Aging | 1 | 1994 | 8650 | 0.000 |
Why?
|
| Lymphocytes | 1 | 1983 | 2610 | 0.000 |
Why?
|
| Erythrocytes | 1 | 1983 | 2413 | 0.000 |
Why?
|
| Prostatic Neoplasms | 1 | 1989 | 11336 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 1983 | 11471 | 0.000 |
Why?
|